Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2018) 56 GP237 | DOI: 10.1530/endoabs.56.GP237

ECE2018 Guided Posters Thyroid Cancer - Translational (10 abstracts)

Comparison in survival of the seventh and eighth editions of the American Joint Commision on Cancer in a Spanish cohort of differentiated thyroid carcinoma: Cadit-CAM Study

Julia Sastre 1 , Belvis Torres 2 , Silvia Aznar 3 , Visitación Alvarez 4 , Manuel Delgado 5 , Javier Gonzalez 6 , Ivan Quiroga 7 , Sandra Herranz 4 , Jose Joaquin Alfaro 3 & Miguel Aguirre 5

1Complejo Hospitalario de Toledo, Toledo, Spain; 2Hospital General La Mancha Centro, Alcazar de San Juan, Spain; 3Complejo Hospitalario Universitario de Albacete, Albacete, Spain; 4Hospital Universitario de Guadalajara, Guadalajara, Spain; 5Hospital General Universitario de Ciudad Real, Ciudad Real, Spain; 6Hospital Virgen de la Luz, Cuenca, Spain; 7Hospital Nuestra Señora del Prado, Talavera de la reina, Spain.

Background and objective: The AJCC-TNM system is optimized to predict survival in patients with cancer. Since January 2018, the new eighth edition of this staging system will be used to classify patients diagnosed of differentiated thyroid carcinoma (DTC). This study aims to compare the seventh and eighth editions of the AJCC-TNM system in a Spanish Cohort of DTC.

Patients and Methods: The Cadit-CAM study was designed to evaluate characteristics of patients diagnosed of DTC in Castilla La Mancha (CAM), a region in the central part of Spain, during 15 years (from 2001 to 2015). The cohort in Cadit-CAM study included 1434 patients from seven hospitals. Staging criteria for the seventh and eighth editions were applied to the cohort. Disease Specific Survival (DSS) were calculated using the Kaplan-Meier method. Multivariate Cox proportional hazards model were used to estimate the association of each stage with survival in both editions.

Results: 1426 patients were analyzed, 77% were women, with a mean age at diagnosis of 48.3 (15.6) years (y) and a mean follow up period of 5.8 (3.9) y, 92% papillary carcinomas. When TNM-8 was applied 26.1% of the patients were down-staged. In patients with < 55 years at diagnosis (n: 947) 15.3% were reclassified and in patients >=55 years at diagnosis (N: 479) 50.1% were downgraded. The 10-years DSS rates in TNM-7 I, II, III and IV stages were 99.9, 95.7, 98.7 and 49.9% respectively. The 10-years DSS rates in TNM-8 stages were 99,8% (I), 89,1% (II), 42,6% (III) and 39,0% (IV) respectively.

Conclusion: A significant number of patients with DCT were down-staged from the seventh to the eighth edition in this cohort of Spanish patients. There was greater separation of survival curves based on disease stage using the eighth edition.

Volume 56

20th European Congress of Endocrinology

Barcelona, Spain
19 May 2018 - 22 May 2018

European Society of Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.